Ranked #2,299 of 8,699 institutional investors
Boxer Capital Management, LLC
San Diego, CA
$1.04B
US stock portfolio at live prices · today −$840K (−0.08%)
Market closed. Prices as of Nov 20, 9:11 AM ET
- Value at quarter end (Q3 2026)
- $1.15B
- Change from Q2 2026
- −$177.1M (−13.34%)
- Positions
- 44 · 12 new, 22 sold out
- Filed
- Nov 16, 2026
Not counted in the ranking: none$58.0M of holdings we could not match to a US listing are included at their reported quarter-end value.
Holdings
Q3 2026 13F, live pricesTNGX 22.9%KOD 13.9%REPL 7.90%RVMD 7.65%KYMR 6.01%
| Stock | Shares | Value, live | % of portfolio | vs Q2 2026 |
|---|---|---|---|---|
| TNGX Tango Therapeutics, Inc. | 10,526,219 | $239M | 22.9% | Reduced −3% |
| KOD Kodiak Sciences Inc. | 1,477,600 | $145M | 13.9% | Unchanged |
| REPL Replimune Group, Inc. | 4,278,159 | $82.3M | 7.90% | Added +7% |
| RVMD Revolution Medicines, Inc. | 500,000 | $79.7M | 7.65% | Unchanged |
| KYMR Kymera Therapeutics, Inc. | 524,551 | $62.6M | 6.01% | Added +22% |
| SRZN Surrozen, Inc. | 1,360,683 | $41.7M | 4.01% | Added +23% |
| ABVX ABIVAX Société Anonyme | 474,971 | $38.3M | 3.68% | Reduced −21% |
| SYRE Spyre Therapeutics, Inc. | 283,054 | $27.6M | 2.65% | Added +183% |
| AMLX Amylyx Pharmaceuticals, Inc. | 893,153 | $23.4M | 2.25% | Added +12% |
| QTTB Q32 Bio Inc. | 2,577,642 | $21.9M | 2.10% | Reduced −18% |
| CORT Corcept Therapeutics Incorporated | 335,500 | $21.8M | 2.09% | Unchanged |
| PTGX Protagonist Therapeutics, Inc. | 170,000 | $21.1M | 2.02% | Unchanged |
| DFTX Definium Therapeutics, Inc. | 683,615 | $20.2M | 1.93% | Reduced −32% |
| IRD Opus Genetics, Inc. | 4,533,660 | $18.5M | 1.78% | Added +61% |
| PGEN Precigen, Inc. | 4,320,339 | $18.0M | 1.72% | Reduced −16% |
| CELC Celcuity Inc. | 286,239 | $16.1M | 1.55% | Reduced −31% |
| QUIT Achieve Life Sciences, Inc. | 2,150,000 | $12.6M | 1.21% | New |
| TRAX First Tracks Biotherapeutics, Inc. | 240,000 | $10.7M | 1.02% | New |
| CCCC C4 Therapeutics, Inc. | 4,150,000 | $10.1M | 0.97% | New |
| SABS SAB Biotherapeutics, Inc. | 2,500,000 | $7.3M | 0.70% | New |
| MAZE Maze Therapeutics, Inc. | 175,465 | $5.7M | 0.55% | New |
| STTK Shattuck Labs, Inc. | 1,175,396 | $5.3M | 0.51% | Added +18% |
| CYTK Cytokinetics, Incorporated | 100,000 | $5.1M | 0.49% | Unchanged |
| ANTX AN2 Therapeutics, Inc. | 944,035 | $4.9M | 0.47% | Added +26% |
| CAPR Capricor Therapeutics, Inc. | 642,837 | $4.8M | 0.46% | Reduced −54% |
| CTNM Contineum Therapeutics, Inc. | 494,000 | $4.5M | 0.43% | Unchanged |
| PALI Palisade Bio, Inc. | 4,799,875 | $4.4M | 0.43% | Unchanged |
| CGEM Cullinan Therapeutics, Inc. | 450,000 | $4.1M | 0.39% | New |
| ETRA Electra Therapeutics, Inc. | 450,000 | $4.0M | 0.39% | New |
| RLAY Relay Therapeutics, Inc. | 200,000 | $3.2M | 0.31% | Reduced −56% |
| ATTO Attovia Therapeutics, Inc. | 200,000 | $3.1M | 0.30% | New |
| PMVP PMV Pharmaceuticals, Inc. | 2,050,000 | $2.7M | 0.26% | New |
| SRPT Sarepta Therapeutics, Inc. | 150,000 | $2.1M | 0.20% | Unchanged |
| EDSA Edesa Biotech, Inc. | 937,363 | $2.0M | 0.20% | Added +357% |
| KZIA Kazia Therapeutics Limited | 371,500 | $2.0M | 0.19% | Reduced −34% |
| CLNN Clene Inc. | 477,515 | $1.7M | 0.16% | Unchanged |
| ZNTL Zentalis Pharmaceuticals, Inc. | 1,013,555 | $1.4M | 0.13% | New |
| NRIX Nurix Therapeutics, Inc. | 100,000 | $1.4M | 0.13% | Unchanged |
| SION Sionna Therapeutics, Inc. | 391,723 | $1.2M | 0.11% | New |
| ACRS Aclaris Therapeutics, Inc. | 300,000 | $1.1M | 0.10% | New |
| ALLO Allogene Therapeutics, Inc. | 1,500,000 | $1.0M | <0.1% | Unchanged |
| NMRA Neumora Therapeutics, Inc. | 954,052 | $331K | <0.1% | Reduced −52% |
| MIST Milestone Pharmaceuticals Inc. | 666,666 | $266K | <0.1% | Unchanged |
| KPTIQ Karyopharm Therapeutics Inc. | 127,536 | $4K | <0.1% | Reduced −58% |
Sold out in Q3 2026
| Stock | Shares held at Q2 2026 | Worth today |
|---|---|---|
| PCVX Vaxcyte, Inc. | 325,000 | $19.0M |
| VIR Vir Biotechnology, Inc. | 1,866,000 | $16.6M |
| PRAX Praxis Precision Medicines, Inc. | 46,457 | $14.4M |
| PTCT PTC Therapeutics, Inc. | 200,000 | $11.7M |
| CRVS Corvus Pharmaceuticals, Inc. | 1,100,000 | $11.0M |
| OCUL Ocular Therapeutix, Inc. | 1,300,000 | $7.6M |
| COGT Cogent Biosciences, Inc. | 225,000 | $6.2M |
| ODTX Odyssey Therapeutics, Inc. | 275,000 | $5.0M |
| INO Inovio Pharmaceuticals, Inc. | 2,844,994 | $4.9M |
| MLTX MoonLake Immunotherapeutics | 275,000 | $3.0M |
| LBRX LB Pharmaceuticals Inc | 70,000 | $2.8M |
| ORIC ORIC Pharmaceuticals, Inc. | 350,000 | $2.7M |
| RLMD Relmada Therapeutics, Inc. | 842,106 | $2.6M |
| AVTX Avalo Therapeutics, Inc. | 375,000 | $2.5M |
| SLDB Solid Biosciences Inc. | 300,000 | $1.9M |
| FTH Faeth Therapeutics, Inc. | 180,505 | $1.6M |
| GPCR Structure Therapeutics Inc. | 75,000 | $1.3M |
| PEPG PepGen Inc. | 272,892 | $1.1M |
| IVVD Invivyd, Inc. | 1,500,000 | $669K |
| MPLT MapLight Therapeutics, Inc. | 75,000 | $482K |
| UPB Upstream Bio, Inc. | 150,000 | $300K |
| RGNX REGENXBIO Inc. | 15,000 | $108K |